LUND, Sweden, June 30, 2020 /PRNewswire/ -- Immunovia
AB (publ) ("Immunovia") today announced the company's long-term
market penetration target of 30% for IMMray™ PanCan-d, after
reimbursement and widespread insurance coverage is
achieved.
As previously announced, Immunovia recently secured one of the
largest funding raises for an EU-based diagnostics company,
providing a strong financial position ahead of the company's first
product launch based on the IMMray™ platform.
Immunovia's first to market product IMMray™ PanCan-d, is a
long-sought solution for the unmet need of early and accurate
detection of pancreatic cancer (PDAC).
IMMray™ PanCan-d will be commercially launched in
the United States in the fourth
quarter 2020. This will be followed by a European roll-out of
IMMray™ PanCan-d and, subsequently, in other markets.
There are more than 7 million eligible patients annually and no
existing accurate diagnostics option on the market. Immunovia
targets a long-term market penetration of 30% after reimbursement
and widespread coverage. The current size of the addressable market
for IMMray™ PanCan-d is estimated to exceed USD 4 billion in EU and United States, across the three risk groups
that the company targets: Hereditary/Familial, Early Symptoms and
Newly Onset Diabetes after 50 years of age.
Guided by Pancreatic ductal adenocarcinoma (PDAC) Key
Opinion Leaders, Immunovia's IMMray™ PanCan-d targets these
well-defined high-risk groups as well as bottlenecks in current
healthcare processes, by providing differential diagnosis in the
detection of PDAC. This will result in patients and the healthcare
systems reaping maximum benefits. Additionally, this supports one
of Immunovia's main objectives which is to have IMMray™ PanCan-d be
included in respective countries' National Guidelines.
"Immunovia will be the first to market with a solution to
diagnose pancreatic cancer earlier and accurately, a major clinical
breakthrough. Immunovia's vision is to become the undisputed market
leader for blood-based diagnosis of pancreatic cancer," comments
Mats Grahn, CEO, "I am confident and
strongly believe that Immunovia will capture a very significant
portion of the market."
About Pancreatic Cancer
In the United States,
Pancreatic ductal adenocarcinoma (PDAC) has surpassed
breast cancer as the third deadliest cancer with an increasing
mortality rate. PDAC is projected to become the second most deadly
cancer by 2030. The high mortality rate is primarily due to the
late detection of PDAC and its vague early stage symptoms. Today,
>80% of patients are being diagnosed so late that no treatment
options are available. Earlier detection of PDAC, has the potential
to improve five-year survival from currently 7-8% up to 50%, using
the current methods of treatment (resection by surgery).
This is information that Immunovia is obliged to make public
pursuant to the EU Market Abuse Regulation. The information was
submitted for publication, through the agency of the contact person
set out above, at 8:45 CET on
June 30, 2020.
About Immunovia
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer and autoimmune diseases based on Immunovia's
proprietary test platform called IMMray™. Tests are based on
antibody biomarker microarray analysis using advanced
machine-learning and bioinformatics to single-out a set of relevant
biomarkers that indicate a certain disease. Thus, forming a unique
"disease biomarker signature".
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is
currently entering the final validation for sales start Q4
2020. When validated, IMMray™ PanCan-d will be the first
blood-based test for early diagnosis of pancreatic cancer on the
market, with a potential to significantly improve patient survival
and outcome.
Immunovia Dx Laboratories located in Marlborough, Massachusetts, USA and
Lund, Sweden will provide
laboratory testing services in two accredited reference
laboratories.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
For more information, please contact:
Julie Silber
Director of Investor Relations, Immunovia
Email: julie.silber@immunovia.com
Tel: +46-7-93-486-277
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/immunovia-targeting-long-term-market-penetration-of-30--for-immray--pancan-d,c3144600
The following files are available for download:
https://mb.cision.com/Main/13121/3144600/1271622.pdf
|
Release
|